High-Dose Celecoxib for Pain After Pediatric Tonsillectomy: A Randomized Controlled Trial.

Area of Science:

• Pediatric Surgery
• Pain Management
• Pharmacology

Background:

• Pediatric tonsillectomy frequently results in significant postoperative pain.
• Standard doses of nonsteroidal anti-inflammatory drugs like celecoxib offer modest pain relief and have not been definitively linked to increased bleeding risk.

Purpose of the Study:

• To evaluate the efficacy and safety of high-dose celecoxib (double the standard pediatric dose) for managing pain following pediatric tonsillectomy.
• To determine if high-dose celecoxib reduces the need for opioid analgesics and assess its impact on bleeding and other adverse events.

Main Methods:

• A randomized, double-blind trial was conducted involving children aged 3 to 11 years undergoing tonsillectomy.
• Participants received either high-dose celecoxib (6 mg/kg/dose) or a placebo twice daily for up to 10 days, supplemented with acetaminophen and oxycodone as needed.
• Pain, coanalgesic consumption, diet, and activity were recorded by subjects.

Main Results:

• High-dose celecoxib significantly reduced opioid consumption by 52% in children with prolonged pain (P = .02) and showed a trend towards reduced consumption overall (P = .03).
• The drug demonstrated a greater benefit in the prolonged pain group compared to the lesser pain group (P = .006).
• Incidence of adverse events and minor hemorrhage was similar between the celecoxib and placebo groups.

Conclusions:

• High-dose celecoxib is an effective and safe option for controlling post-tonsillectomy pain in children, notably reducing narcotic requirements.
• The analgesic effect of high-dose celecoxib appears more pronounced in children experiencing more severe or prolonged pain.
• Celecoxib can be considered a viable alternative to ibuprofen for pain management after pediatric tonsillectomy.